Quotables
"I think there is a world market for maybe five computers."
Thomas Watson, chairman of IBM ; 1943
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183231 | Substituted propane phosphinic acid derivatives The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds... | 05/22/2012 |
| 8168616 | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof. ... | 05/01/2012 |
| 7550448 | Therapeutic compounds Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed. ... | 06/23/2009 |
| 7547685 | Therapeutic substituted pyrrolidone compounds Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed herein. Details are provided herein. Compositions, methods, and medicaments related thereto are also disclosed. ... | 06/16/2009 |
| 7410956 | Caspase inhibitor prodrugs The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. ... | 08/12/2008 |
| 7348318 | α-Amino-N-(diaminophosphinyl)lactam derivatives There are disclosed a novel α-amino-N-(diaminophosphinyl)lactam derivative represented by general formula (1): wherein, for example, A is a hydrogen atom or a substituent such as a lower alkyl group or the like; W, X, Y an... | 03/25/2008 |
| 7320967 | Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair The invention relates to a cosmetic composition containing at least one 15-hydroxy-prostaglandin dehydrogenase inhibitor and cosmetically acceptable excipients. It also relates to a method of cosmetic treatment for promoting the growth and/or preventing or delaying ... | 01/22/2008 |
| 7294647 | Kappa agonist compounds and pharmaceutical formulations thereof Compounds having kappa opioid agonist activity, compositions containing them and 5 method of using them as analgesics and pruritic agents are provided. The compounds of formulae I, II, III and IV have the structure: ... | 11/13/2007 |
| 7276492 | Use of ACE inhibitors for treatment of patients suffering from behavioral disorders A method for the treatment of a patient suffering from an endogenous behavioral disorder in order to ameliorate at least some behavioral aspects of the disorder, the method comprising administering to the patient a therapeutic quantity of at least one ACE inhibitor.... | 10/02/2007 |
| 7268124 | Geranylgeranyl pyrophosphate synthase inhibitors The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use. ... | 09/11/2007 |
| 7256158 | 2,4,5,-trisubstituted phenylketo-enols for use as pesticides and herbicides The invention relates to new phenyl-substituted cyclic ketoenols of the formula (I) in which Het represents one of the groups w... | 08/14/2007 |
| 7255984 | Combination therapy for osteoporosis Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis. ... | 08/14/2007 |
| 7226593 | Methods of treating cachexia with chimeric anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α(TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and ch... | 06/05/2007 |
| 7217426 | Coatings containing polycationic peptides for cardiovascular therapy Coatings for implantable medical devices and methods for fabricating the same are disclosed. The coatings include a region containing a polycationic peptide, such as, for example, the polycationic peptide known as R7. ... | 05/15/2007 |
| 7214701 | Active substance combinations having insecticidal and acaricdal properties The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ... | 05/08/2007 |
| 7214376 | Methods of inhibiting TNFα in patients with neoplastic disease Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 05/08/2007 |
| 7208481 | Aminodiphosphonate apolipoprotein E modulators The present invention relates to methods of use of aminodiphosphonate to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states. ... | 04/24/2007 |
| 7192584 | Methods of treating psoriasis with anti-TNF antibodies The invention relates to anti-TNF antibodies, fragments, regions and derivatives thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in methods of treating psoriasis, as well as polynucleotides coding for murine and chimeric anti-TNF... | 03/20/2007 |
| 7185127 | Method and an apparatus to efficiently handle read completions that satisfy a read request A method and an apparatus to efficiently handle read completions that satisfy a read request are presented. The apparatus comprises a first port to receive data that partially satisfies a read request, a second port, wherein the data is forwarded via the second port... | 02/27/2007 |
| 7179836 | Chemical compounds Thiophene derivatives are described herein. The described invention also includes methods of making such thiophene derivatives as well as methods of using the same in the treatment of diseases. ... | 02/20/2007 |
| 7179466 | Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 02/20/2007 |
| 7169386 | Methods of treating inflammation associated with viral infection with anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 01/30/2007 |
| 7166639 | NF-κB inhibitors The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in ... | 01/23/2007 |
| 7160995 | DNA encoding anti-TNF antibodies and peptides Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 01/09/2007 |
| 7135178 | Methods of treating disseminated intravascular coagulation using anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful for therapy of TNFα-mediated pathologies and conditions, including vascular inflammatory pathologies. ... | 11/14/2006 |
| 7122677 | NK1 antagonists A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5... | 10/17/2006 |
| 7115664 | Peptidomimetic ligands for cellular receptors and ion channels One aspect of the present invention relates to novel peptidomimetic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-co... | 10/03/2006 |
| 7109185 | Pharmaceutical formulations comprising indolinone derivatives The present invention is directed to formulations comprising 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Methods of treating diseases related to abnormal PK activity utilizing the formulations compri... | 09/19/2006 |
| 7109186 | HIV integrase inhibitors The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds ... | 09/19/2006 |
| 7105556 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, X1 is C or N, and R1, R2, R2a, R2b, R2c, R3, Y, A, m, n, X2 | 09/12/2006 |
| 7094256 | Coatings for implantable medical device containing polycationic peptides Coatings for implantable medical devices and methods for fabricating the same are disclosed. The coatings include carboxylated acrylates and polycationic peptides, for example R7. ... | 08/22/2006 |
| 7084153 | Medicaments comprising steroids and a novel anticholinergic A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X− is an anio... | 08/01/2006 |
| 7084138 | Active ingredient combinations with insecticidal and acaricidal properties The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing (a) cyclic ketoenols having the formula in which the gro... | 08/01/2006 |
| 7070798 | Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine A coating for an implantable medical device is disclosed. The coating comprises a polymer and an amino acid chemically bonded, attached or conjugated to the polymer. In one embodiment, the coating can include a therapeutic substance. In lieu of bonding the amino aci... | 07/04/2006 |
| 7070775 | Recombinant A2-specific TNFα specific antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 07/04/2006 |
| 7071183 | Use of inhibitors of the renin-angiotensin system It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or i... | 07/04/2006 |
| 7060692 | Active ingredient combinations comprising insecticidal and acaricidal properties The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing (a) cyclic ketoenols having the formula in which the gro... | 06/13/2006 |
| 7056523 | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine An implantable medical device, such as a stent, is disclosed comprising an amino acid or a polypeptide bonded to a plasma polymerized film layer formed on the device. A method of manufacturing the same is also disclosed. ... | 06/06/2006 |
| 7049283 | Pharmaceutical compositions for the oral delivery of pharmacologically active agents Solid pharmaceutical compositions suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacol... | 05/23/2006 |
| 7045511 | Fosinopril formulation A pharmaceutical formulation is provided comprising fosinopril which is the prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. The formulation is characterized by comprising in the range of about 0.25 to about 5% glyceryl dibehenate which has... | 05/16/2006 |
